The CNAT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNAT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CNAT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CNAT Detailed Price Forecast - CNN Money||View CNAT Detailed Summary - Google Finance|
|View CNAT Detailed Summary - Yahoo! Finance||View CNAT Stock Research & Analysis - Zacks.com|
|View CNAT Trends & Analysis - Trade-Ideas||View CNAT Major Holders - Barrons|
|View CNAT Call Transcripts - NASDAQ||View CNAT Breaking News & Analysis - Seeking Alpha|
|View CNAT Annual Report - CompanySpotlight.com||View CNAT OTC Short Report - OTCShortReport.com|
|View CNAT Fundamentals - TradeKing||View CNAT SEC Filings - Bar Chart|
|View Historical Prices for CNAT - The WSJ||View Performance/Total Return for CNAT - Morningstar|
|View the Analyst Estimates for CNAT - MarketWatch||View the Earnings History for CNAT - CNBC|
|View the CNAT Earnings - StockMarketWatch||View CNAT Buy or Sell Recommendations - MacroAxis|
|View the CNAT Bullish Patterns - American Bulls||View CNAT Short Pain Metrics - ShortPainBot.com|
|View CNAT Stock Mentions - StockTwits||View CNAT Stock Mentions - PennyStockTweets|
|View CNAT Stock Mentions - Twitter||View CNAT Investment Forum News - Investor Hub|
|View CNAT Stock Mentions - Yahoo! Message Board||View CNAT Stock Mentions - Seeking Alpha|
|View Insider Transactions for CNAT - SECform4.com||View Insider Transactions for CNAT - Insider Cow|
|View CNAT Major Holdings Summary - CNBC||View Insider Disclosure for CNAT - OTC Markets|
|View Insider Transactions for CNAT - Yahoo! Finance||View Institutional Holdings for CNAT - NASDAQ|
|View CNAT Stock Insight & Charts - FinViz.com||View CNAT Investment Charts - StockCharts.com|
|View CNAT Stock Overview & Charts - BarChart||View CNAT User Generated Charts - Trading View|
Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Posted on Wednesday April 18, 2018
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the publication1 of results from both in vitro and in vivo studies of its pan-caspase inhibitor, IDN-7314, demonstrating reductions of hepatic tissue factor-driven coagulation. Patients with liver cirrhosis can suffer caspase-driven complications of both excessive bleeding and excessive clotting. The current studies suggest that a pan-caspase inhibitor may have the potential to reduce excessive clotting in patients with severe liver disease.
How Analysts Rate Regenxbio and Peers in April 2018
Posted on Friday April 13, 2018
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
Posted on Wednesday April 11, 2018
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...